SCHEMBL5423554

SCHEMBL5423554

CC(C)OC(=O)c1ccc(OC/C(=N/O)c2ccc3c(c2)C(C)(C)CCC3(C)C)cc1O

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 7/20 0.64
CYP3A4 P08684 6/20 0.64
CYP26B1 Q9NR63 4/20 0.63
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
PPARG P37231 2/20 0.38
RXRA P19793 7/20 0.38
RXRB P28702 6/20 0.38
RXRG P48443 5/20 0.38
RARB P10826 3/20 0.37
RARG P13631 3/20 0.37
RARA P10276 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5423557 1.00 CYP26A1 (0.64) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL8908692 0.89 CYP26A1 (0.77) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL8908697 0.89 CYP26A1 (0.77) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL5421801 0.89 CYP26A1 (0.62) CYP26A1CYP3A4CYP26B1PPARGRXRA
SCHEMBL5421804 0.89 CYP26A1 (0.62) CYP26A1CYP3A4CYP26B1PPARGRXRA
SCHEMBL5431263 0.88 CYP3A4 (0.61) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL5429594 0.87 CYP26A1 (0.65) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL5429598 0.87 CYP26A1 (0.65) CYP26A1CYP3A4CYP26B1CA12CA1
SCHEMBL5081220 0.87 CYP26A1 (0.76) CYP26A1CYP3A4CYP26B1RXRARXRB
SCHEMBL5081216 0.87 CYP26A1 (0.76) CYP26A1CYP3A4CYP26B1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249710-A1 Biaromatic compounds and cosmetic/pharmaceutical applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-10-25 US claimed
US-20070249710-A1 Biaromatic compounds and cosmetic/pharmaceutical applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249710-A1 Biaromatic compounds and cosmetic/pharmaceutical applications thereof RARG, RARA, RARB CYP26A1 378/4885CYP3A4 2007/4885CYP26B1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.